The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling
Open Access
- 17 March 2026
- journal article
- review article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3) , e70643
Abstract
Background: Metabolic reprogramming is a key cancer hallmark, with dysregulated fatty acid metabolism critical for tumorigenesis and progression. The acyl‐CoA synthetase long‐chain (ACSL) family (ACSL1–ACSL6) catalyzes ATP‐dependent activation of long‐chain fatty acids into acyl‐CoA, a bioactive intermediate in lipid synthesis, β‐oxidation, membrane biogenesis, and signal transduction. Dysregulated ACSL expression is widespread in malignancies, but their non‐metabolic functions (ferroptosis regulation, tumor immune microenvironment remodeling) and translational potential of targeted therapies remain to be systematically summarized. Methods: This narrative review comprehensively synthesizes existing literature on the biological functions of ACSL family members in cancer. We retrieved and analyzed studies focusing on ACSL‐mediated lipid metabolic reprogramming, ferroptosis modulation, and immunomodulatory effects, with particular emphasis on isoform‐specific mechanisms and the context‐dependent roles (pro‐tumorigenic or tumor‐suppressive) of the ACSL family across different cancer types. Additionally, we summarized emerging therapeutic strategies targeting ACSL isoforms and their translational potential. Results: ACSL isoforms exert distinct context‐dependent effects:ACSL1 promotes immunosuppressive TIME via M2 macrophage polarization;ACSL3/4 have antagonistic roles in ferroptosis;ACSL5 exerts dual effects via lipid metabolism, apoptosis, and immunity;ACSL6 involves autophagy and hematological malignancies. Dysregulation correlates with tumor progression, drug resistance, and immunotherapy response, while emerging ACSL‐targeted drugs show substantial translational potential. Conclusions: The ACSL family serves as a key regulatory node integrating lipid metabolism, ferroptosis, and tumor immunity. Its isoform‐specific mechanisms and context‐dependent characteristics highlight its potential as a precise therapeutic target. Future research should focus on optimizing isoform‐selective inhibitors, clarifying their synergistic effects with existing therapies (e.g., immune checkpoint inhibitors, radiotherapy), and validating their translational efficacy through clinical trials to advance the development of innovative cancer treatment strategies.Keywords
Funding Information
- National Science and Technology Major Project (2023ZD0502001)
- National Natural Science Foundation of China (82473040)
This publication has 233 references indexed in Scilit:
- Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunctionMolecular Oncology, 2025
- N‐glycosylation Modification of CTSD Affects Liver Metastases in Colorectal CancerAdvanced Science, 2024
- Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer ImmunotherapyAngewandte Chemie International Edition, 2024
- Iridium(III) Photosensitizers Induce Simultaneous Pyroptosis and Ferroptosis for Multi‐Network Synergistic Tumor ImmunotherapyAngewandte Chemie International Edition, 2024
- A Robust ROS Generation and Ferroptotic Lipid Modulation Nanosystem for Mutual Reinforcement of Ferroptosis and Cancer ImmunotherapyAdvanced Healthcare Materials, 2024
- Blocking ACSL6 Compromises Autophagy via FLI1‐Mediated Downregulation of COLs to Radiosensitize Lung CancerAdvanced Science, 2024
- Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast CancerAdvanced Materials, 2022
- Highly Efficient Far‐Red/NIR‐Absorbing Neutral Ir(III) Complex Micelles for Potent Photodynamic/Photothermal TherapyAdvanced Materials, 2021
- Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non‐small cell lung cancerMolecular Oncology, 2020
- Fusion ofTEL/ETV6 to a novelACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13)Genes, Chromosomes and Cancer, 1999